about
Direct and indirect mechanisms of KLK4 inhibition revealed by structure and dynamics.Diverse cyclic seed peptides in the Mexican zinnia (Zinnia haageana).Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1Optimization of the cyclotide framework to improve cell penetration properties.In vivo efficacy of anuran trypsin inhibitory peptides against staphylococcal skin infection and the impact of peptide cyclizationInhibition of Human Prolyl Oligopeptidase Activity by the Cyclotide Psysol 2 Isolated from Psychotria solitudinum.Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors.Probing the interaction mechanism of small molecule inhibitors with matriptase based on molecular dynamics simulation and free energy calculations.Efficient recombinant expression of SFTI-1 in bacterial cells using intein-mediated protein trans-splicing.Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration.A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Review cyclic peptides on a merry-go-round; towards drug design.Spliced analogues of trypsin inhibitor SFTI-1 and their application for tracing proteolysis and delivery of cargos inside the cells.Progress with peptide scanning to study structure-activity relationships: the implications for drug discovery.The role of type II transmembrane serine protease-mediated signaling in cancer.Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.Cyclotides: Overview and Biotechnological Applications.Expanding the scope of N → S acyl transfer in native peptide sequences.Evaluating the cytotoxicity of flaxseed orbitides for potential cancer treatment.Easy and rapid binding assay for functional analysis of disulfide-containing peptides by a pull-down method using a puromycin-linker and a cell-free translation system.Cyclotides, a versatile ultrastable micro-protein scaffold for biotechnological applications.A Facile N-Mercaptoethoxyglycinamide (MEGA) Linker Approach to Peptide Thioesterification and Cyclization.Design and chemical syntheses of potent matriptase-2 inhibitors based on trypsin inhibitor SFTI-1 isolated from sunflower seeds.Biodistribution of the cyclotide MCoTI-II, a cyclic disulfide-rich peptide drug scaffold.Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.Exploitation of the Ornithine Effect Enhances Characterization of Stapled and Cyclic Peptides.An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease.Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1.Bioactivity-Guided Isolation of Neuritogenic Factor from the Seeds of the Gac Plant (Momordica cochinchinensis).
P2860
Q30825171-1011BCEE-30D2-4E30-BE01-34FD21F701F2Q31111152-EF7F10A9-BA51-491E-AC65-17AF9370773DQ35023006-DFDF68CD-EF4A-46AE-84AF-261B4C5D23BEQ35063455-86C8588A-8620-40A5-9A2A-7EF7CD9E3A59Q35169096-FFB75E36-346D-4635-A704-89A916E24473Q35610164-0A3BBD2A-AD91-494A-BC17-D7969CA4B2B7Q35696184-85EC88EF-516D-43D8-AA5D-C3B71CE5DCEDQ35945845-96320DC9-535E-4978-94C8-B9011B0B542FQ36017639-A8137182-EFF8-4D07-98B3-770E07C74A64Q36321375-CC414011-64F5-46C4-87E3-E470C6AFF343Q37098934-15B5EA65-AB53-46E0-8854-4B60B5AD8D65Q38184632-F3D9A94C-7347-4EFF-A521-BB97FB05D20CQ38476515-142C8471-9259-45AA-9B60-7E3011E15370Q38746354-50CCD4A0-F595-47BB-B3C1-6827DFFA9C99Q38867099-A3766FA3-2D6F-4E8A-8E2E-7233FAEDED83Q39015415-550E7709-25BE-4466-84DC-D68AFDC3373EQ39061621-95C08FE8-4B2D-4725-9D4B-E79E2FFBDDEEQ39330201-E14A74BD-6769-4E5F-B2C0-8B1A1676064AQ40845023-5859B674-8732-4B64-A693-BF5D1B704CC3Q41680122-1244ED0F-4836-42D0-BE0E-D85EAA3B103AQ42176320-5734AB01-891F-471E-90AF-481420166649Q46003077-F49FA094-3116-46F2-A5BF-71AC64AFCE5EQ48202682-4B457738-88EE-4302-87F8-935462BB336DQ48363355-4FB2AE15-00F8-4B89-9E0D-4A8FDB89E74DQ48869308-1832E784-0D08-41A4-9B80-4B94786D00B4Q49545332-1BEA17AD-BE1E-4651-964F-007B4B5183FFQ50881656-B1E161C7-B931-477C-863E-75487D56F9B4Q50888630-1B4105BC-C9B9-4FAF-A870-9DB463E4DE0EQ52615555-BE2F19E3-6440-4C89-9EAE-2960F7D58053Q55465960-5D5A8853-FEB1-49C1-A319-FD25BFCE6C8D
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
High-affinity cyclic peptide matriptase inhibitors
@en
type
label
High-affinity cyclic peptide matriptase inhibitors
@en
prefLabel
High-affinity cyclic peptide matriptase inhibitors
@en
P2093
P2860
P50
P356
P1476
High-affinity cyclic peptide matriptase inhibitors
@en
P2093
Christian P Sommerhoff
Kerry Dunse
Maresa Grundhuber
Pedro Quimbar
P2860
P304
13885-13896
P356
10.1074/JBC.M113.460030
P407
P577
2013-04-02T00:00:00Z